Ursula Havemann‐Reinecke

Universitätsmedizin Göttingen — Germany

Medicine · Health Sciences

29h-index5.1kcitations151works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Treatment of Major Depression(28), Cannabis and Cannabinoid Research(26), Neurotransmitter Receptor Influence on Behavior(25), Schizophrenia research and treatment(23), Tryptophan and brain disorders(16)

Publications151 total

Bewertung von Empfehlungen zum risikoarmen Umgang mit Alkohol, Cannabis, Glücksspielen und Computerspielen – Stand des Wissens
Der Nervenarzt·2025Open Access
How to Determine a Therapeutic Reference Range for a Psychotropic Drug Systematically? Recommendations of the TDM Task Force of the AGNP
Therapeutic Drug Monitoring·2025· 4 citedOpen Access
Pharmakotherapie bei Cannabisabhängigkeit
Suchttherapie·2024Open Access
Patienten- und Qualitätsmerkmale bei der Behandlung mit Disulfiram („Antabus“) im deutschsprachigen „Netzwerk alkoholaversive Pharmakotherapie“
Der Nervenarzt·2024· 4 citedOpen Access
Empfehlungen zum Umgang mit Alkohol
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice·2024· 4 citedOpen Access
Venlafaxine’s therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis
Psychopharmacology·2023· 21 citedOpen Access
Levomethadone Therapeutic Drug Monitoring to Aid Opioid Withdrawal Therapy: A Short Communication
Therapeutic Drug Monitoring·2023Open Access
Therapeutic Reference Range for Olanzapine in Schizophrenia
The Journal of Clinical Psychiatry·2023· 23 citedOpen Access
Kommentare zu M. Adams und T. Effertz (2022): Notwendige Voraussetzungen einer kontrollierten Freigabe von Cannabis und anderer THC-haltiger Produkte
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice·2022Open Access
Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis
Pharmacopsychiatry·2022
Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy
Frontiers in Psychiatry·2022· 23 citedOpen Access
Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder
European Archives of Psychiatry and Clinical Neuroscience·2022· 10 citedOpen Access
Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis
Psychopharmacology·2022· 29 citedOpen Access
Psychosocial stress and cannabinoid drugs affect acetylation of α-tubulin (K40) and gene expression in the prefrontal cortex of adult mice
PLoS ONE·2022· 1 citedOpen Access
Cannabis-Legalisierung: Prävention und Jugendschutz sind nicht verhandelbar
NeuroTransmitter·2022· 4 cited
Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range
Pharmacopsychiatry·2022· 1 cited
The therapeutic reference range for olanzapine revised – how to combine old and new findings
Pharmacopsychiatry·2022· 1 cited
Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis
Pharmacopsychiatry·2022· 1 cited
Drug interactions in patients undergoing opioid maintenance therapy
Pharmacopsychiatry·2022
Is it Time to Reevaluate the Therapeutic Reference Range for the Antidepressant Drug Venlafaxine?
Pharmacopsychiatry·2022
page 1 of 8Next →

Frequent Co-authors

Christoph Hiemke(17), Gerald Zernig(10), Gerhard Gründer(9), Georgios Schoretsanitis(9), Pierre Baumann(9), Andreas Conca(8), Dirk Wedekind(8), Gudrun Hefner(7), Karin Egberts(6), Gerd Laux(6), Rainald Mößner(6), Peter Riederer(6), S. Ulrich(6), Rafał Ryguła(6), Jordi Tomàs-Roig(6), Xenia M. Hart(6), Thomas Messer(5), Michael Paulzen(5), Bruno Pfuhlmann(5), Bernd Schoppek(5)